Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 4Neoplasm Metastasis 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Pheochromocytoma 1Paraganglioma 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive, Peripheral 1Mesothelioma 1Fallopian Tube Neoplasms 1Extensive Stage Lung Small Cell Carcinoma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Ovarian Cancer 1

Interventions

atezolizumab 2Specimen Handling 2Magnetic Resonance Spectroscopy 2talazoparib 1olaparib 1cediranib 1Radiotherapy 1Radiation 1Platinum 1Etoposide 1Cisplatin 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Extensive Stage Lung Small Cell Carcinoma × talazoparib × Clear all
NCT04334941 2026-06-05

Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker

National Cancer Institute (NCI)

Phase 2 Active not recruiting
103 enrolled

Extensive Stage Lung Small Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡